Journal of Clinical Laboratory Analysis · 2017 · 16 citations · 10 references
Life SciencesImmunologyInfectious DiseasesClinical ImmunologyImmunology Of Infectious DiseasesImmunopathologyCell-mediated ImmunityDiagnostic ImmunologyPulmonary TuberculosisT Cell BiologyTuberculosis DiagnosisTuberculosis Diagnostic TestingHigh-sensitivity AssaysInterferon Gamma ProductionInterferon Gamma ResponseInterferon-gamma ResponsesPulmonary Tuberculosis DiagnosisRetrospective Case StudyTuberculosis Antigen DetectionTuberculosis Diagnostics
Objective Tuberculosis ( TB )‐interferon gamma release assay ( IGRA ) test has the characteristics of short time, high specificity, and high sensitivity, but it lacks the correlation research between TB ‐ IGRA test results and body's immune cells, disease progression and prognosis, which is explored in this study. Design A retrospective study was carried out on positive TB ‐ IGRA patients who were infected with TB and diagnosed at our hospital from January 2014 to June 2015. The TB ‐ IGRA , routine blood test, T‐cell subgroup data were collected for statistical analysis. Results TB ‐ IGRA results were in positive proportion to the lymphocytes, CD 4 + T cells and CD 4 + CD 28 + T cells, whereas negative to the Treg cells. Patient with unilateral pulmonary lesion had higher TB ‐ IGRA than those with bilateral pulmonary lesions. After the stimulation of TB ‐specific antigen, the proportion of CD 4 + IFN ‐γ + and CD 8 + IFN ‐γ + T Tcells were both increased and the CD 4 + IFN ‐γ + T had positive correlation with the value of TB ‐ IGRA . Conclusions IFN ‐γ was tested with TB ‐ IGRA in patients with TB by the specific TB T cells and correlated with the lymphocytes, while the lymphocytes also closely related to the host's anti‐ TB immunity and disease outcome. Hence the result of TB ‐ IGRA could reflect the specific anti‐ TB immunity ability of the host, disease progression and prognosis. This study further expands the application scope of TB ‐ IGRA technology in the diagnosis of TB and lays a foundation for clinical practice to understand the immunity state of the patients with TB and the application of auxiliary clinical immunity regulators.
10
Alfonso Zavaleta, María Salas, Armando Peruga et al. · BMC Public Health · 2008 · 196 citations · Full text
Public Health, Health Sciences, Population Health Sciences +17
Philip C. Hill, Roger H. Brookes, Annette Fox et al. · Clinical Infectious Diseases · 2004 · 160 citations